An interventional study of 35-kDa Hyaluronan Fragment (HA35) Chewable Tablet in Gingival Inflammation, Gingival Recession and Post-Dental-Procedure Oral Pain, sponsored by Nakhia Impex LLC. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Nakhia Impex LLC · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Gingivitis with a site in China — 7 open to participants now, 7 under way, 2 of them phase 3. Gingivitis · China.
Among the 18 studies in Gingivitis with a site in China, this one is the 14th largest by planned enrollment of the 15 interventional ones that give a count, is one of 6 that started in 2026, is one of 8 with no phase, and was the 18th registered.
631 studies on the registry are indexed under Gingivitis; 107 are open to participants now.
Browse Gingivitis studies →7 of the 18 studies in Gingivitis with a site in China are open now. Recruiting first, the newest first:
HALEON · Sites in China
Ages 18–70 · Healthy volunteers
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Sites in China
Ages 18–64
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Sites in China, Italy, United Kingdom
Ages 18+ · Healthy volunteers
Colgate Palmolive · Sites in China
Ages 18–70 · Healthy volunteers
Colgate Palmolive · Sites in China
Ages 18–70 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 53 Gingivitis studies recruiting now, 15 (28%) set no upper age limit and 36 (68%) stop at 75 or younger; 11 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 6 started in 2026.
This study's planned enrollment of 30 is below the median of 66 across 507 interventional studies indexed under Gingivitis.
Median enrollment 98 across the 15 interventional studies, 2,000 across the 3 observational. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 18 have an industry lead sponsor. The 10 most frequent:
Nakhia Impex LLC is the lead sponsor of 17 studies on the registry; 2 are open to participants now.
Nakhia Impex LLC has 1 study filed under Gingivitis — fewer than ten, so there is no comparison to draw.
4 of the studies in Gingivitis with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07842978Phase 3Colgate PalmoliveClinical Study Examining the Control of Plaque and Gingivitis | 2027-04 |
| NCT07816406HALEONThe Study to Evaluate the Plaque Control and Anti-Gingivitis Efficacy of a Toothpaste in Chinese Population | 2027-01 |
| NCT07942259Nakhia Impex LLC35-kDa Hyaluronan Fragment (HA35) Chewable Tablets for Gingival Inflammation, Oral Pain and Pharyngeal Discomfort | 2027-01-12 |
| NCT07549347Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityIs Professional Tooth Cleaning Necessary for Managing Gingivitis (Gingival Inflammation) if Subjects Use Intelligent Toothbrushes? | 2027-03-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 18 studies in Gingivitis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To explore efficacy and safety of 35-kDa hyaluronan fragment (HA35) chewable tablets for relief of tooth-gingival pain, periodontal gingival inflammation, mild gingival recession, and pharyngeal itching-pain. Participants chew six tablets per dose, three times daily for 28 consecutive days. Assess subjective oral-pharyngeal symptoms, gingival inflammation, estimated gingival regrowth and safety events.
This is prospective, single-arm, open-label pilot clinical study. Eligible adult participants with periodontal condition, mild gingival recession and oral-gingival pain or pharyngeal discomfort receive HA35 chewable tablets. Each tablet weighs 600 mg containing 300 mg 35-kDa hyaluronan fragment. Subjects chew six tablets each administration (3 tablets on each molar side), three times daily for total 18 tablets/day (5.4 g HA35/day), for 28 consecutive days. Tablets dissolve by saliva in oral cavity after chewing. Evaluations are performed at baseline; 3 minutes post-first dose; 30 minutes post-first dose; Day 1, Day 7, Day 21, Day 28. Investigator assess gingival redness/swelling, exposed root length for estimated gingival regrowth. Subject self-report pain, itch-pain of throat. Exploratory facial-tissue related assessments are performed at Day 28. Adverse events are monitored throughout whole 28-day study period. Target enrollment: 30 adult participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: 35-kDa Hyaluronan Fragment (HA35) Chewable Tablet
Intervention description: Each tablet 600 mg containing 300 mg HA35. Chew six tablets per dose (3 each side molars), three times daily, total 18 tablets/day (5.4 g HA35/day), 28 consecutive days. Tablets dissolve in saliva after chewing.
Primary Outcome Measures
Participant-reported 0-10 numerical rating scale for tooth and gingival pain; 0=no pain,10=worst imaginable pain
Time frame: Baseline, 3 minutes after first administration, Day-1, Day-7, Day-28
Pharyngeal Itching-Pain NRS Score
Participant-reported 0-10 NRS for throat itching and pain;0=no symptom, 10=worst imaginable itch-pain
Time frame: Baseline,30 minutes after first administration, Day-1, Day-7, Day-28
Gingival Inflammatory Redness-Swelling NRS Score
Investigator-rated composite 0-10 score of gingival redness and swelling;0=no inflammation;10=severe gingival redness and swelling
Time frame: Baseline, Day-1, Day-7, Day-21, Day-28
Estimated Gingival Regrowth Length (mm)
Investigator measurement of exposed tooth-root length using 1-mm precision ruler; calculate estimated gingival regrowth from baseline
Time frame: Baseline, Day-21, Day-28
Exploratory Facial-tissue Reduction Score
Investigator visual-tactile 0-10 rating scale (exploratory only): reduction of facial roundness, forehead-skin thickness, eyelid thickness, double-chin prominence;0=no reduction;10=maximum reduction. Exploratory endpoint only
Time frame: Baseline, Day-28
Participant Overall Satisfaction Score
Participant self-reported overall satisfaction 0-10 scale for oral-pharyngeal improvement. 0=most dissatisfied, 10=most satisfied
Time frame: Day-28 end-of-treatment
Adverse Event Incidence
Incidence of product-related adverse events including oral mucosal irritation, hypersensitivity, gastrointestinal discomfort, throat irritation
Time frame: Entire 28-day study period
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Jan 2027, 0 months later.
Of 53 industry-sponsored interventional studies with no phase under Gingivitis, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 5. This study's planned 0 months is below that.
Counting every sponsor, half of 257 studies reached it within 7 months; a quarter within 3 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.